Bevacizumab for non-small-cell lung cancer [1]

New England Journal of Medicine

Volumn 356, Issue 13, 2007, Pages 1373-1375

  Garassino, Marina Chiara ^a   Hollander, Lital ^b   Torri, Valter ^b  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; CISPLATIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; BLEEDING; CHEMICALLY INDUCED DISORDER; HEMOPTYSIS; LUNG DISEASE; LUNG TUMOR; MORTALITY; NOTE; SURVIVAL; CLINICAL TRIAL; DISEASE SEVERITY; LUNG CAVITATION; LUNG HEMORRHAGE; TUMOR LOCALIZATION; CANCER RESEARCH; SURVIVAL RATE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; HEMOPTYSIS; HEMORRHAGE; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; PACLITAXEL; RISK FACTORS; SURVIVAL ANALYSIS; CISPLATIN;

EID: 34047186955     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc070042     Document Type: Letter

References (1)

1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. [Erratum, N Engl J Med 2007;356:318.]